Definium Therapeutics (DFTX) Shares Gain on White House Psychedelic Treatment Initiatives

TLDR

• Definium Therapeutics has publicly expressed support for a new White House Executive Order focused on accelerating mental health innovation, including psychedelic treatments
• The firm is developing DT120 ODT (lysergide tartrate), an exclusive LSD-based formulation, for generalized anxiety disorder (GAD) and major depressive disorder (MDD)
• DT120 holds FDA Breakthrough Therapy Designation, with four Phase 3 trials currently underway
• On April 17, Stifel launched coverage of DFTX with a Buy rating and a $30 price target, compared to the then-current stock price of approximately $22.46
• Insider activity over the past three months shows no purchases and $0.8 million in stock sales

---

(SeaPRwire) –   Definium Therapeutics (DFTX) issued a statement on April 19 endorsing a newly signed White House Executive Order aimed at speeding up access to psychedelic-based mental health treatments. The stock rose 0.98% following this news.

The Executive Order directs federal agencies to prioritize mental health therapies, streamline regulatory pathways, and expand cross-agency collaboration. It specifically highlights psychedelic medicines as potential tools to address the U.S. mental health crisis.

Today, President Donald J. Trump took historic action to remove barriers on psychedelic treatments for serious mental illness — delivering new hope to millions of Americans, especially our veterans. pic.twitter.com/vhLIwRrLqs

— The White House (@WhiteHouse) April 18, 2026

CEO Rob Barrow welcomed the order, describing it as “an important recognition of the persistent unmet treatment needs in serious mental illness.” He noted that the company is advancing a full clinical program for DT120 targeting patients with GAD and MDD.

DT120 ODT is Definium’s flagship drug candidate. It is a pharmaceutically optimized formulation of lysergide tartrate — the tartrate salt form of LSD — developed using Catalent’s Zydis fast-dissolve technology.

The formulation is designed for faster absorption, improved bioavailability, and fewer gastrointestinal side effects compared to standard delivery methods. It acts as a partial agonist at serotonin-2A receptors.

DT120 already holds FDA Breakthrough Therapy Designation. The company currently has four Phase 3 trials in progress, which will be critical for any future market entry.

Stifel Launches Coverage With Buy Rating and $30 Target

Two days before the White House announcement, on April 17, Stifel initiated coverage of DFTX with a Buy rating and a $30 price target. At the time, the stock was trading around $22.46, implying roughly 34% upside to that target.

This coverage launch reflects growing Wall Street interest in the psychedelic medicine space as regulatory momentum builds.

Some Cautionary Indicators

Not all signs point upward. Definium’s GF Score stands at just 38 out of 100, with a profitability rank of 1 out of 10 — a reflection of the company’s pre-revenue, clinical-stage status.

Financial strength ranks higher at 7 out of 10, suggesting the balance sheet is reasonably stable. Momentum scores a 6, aligning with recent price movements.

Insider activity over the last three months paints a mixed picture. There have been zero insider purchases, while insiders sold $0.8 million worth of stock. This one-sided selling doesn’t necessarily signal alarm for a clinical-stage biotech, but it’s worth noting.

The company has a market cap of approximately $2.24 billion.

The White House order aligns with Definium’s existing development roadmap, and the company stated it looks forward to continued collaboration with federal agencies, clinicians, and patient communities.

Definium’s DT120 is currently being evaluated for GAD, MDD, and other serious brain health disorders. The company is headquartered in New York and trades on Nasdaq.